Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?

• Authors: Charles Porter
• Languages of publication: EN

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2016
• Volume: 6
• Issue: 1
• Pages: A11-13

Contributors

author

Charles Porter

• University of Kansas Medical Center, Kansas City, Kansas, United States Correspondence

References

• 1. Kantarjian HM, Giles FJ, Bhalla KN et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117(4): 1141-1145.
• 2. Saglio G, Kim DW, Issaragrisil S et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2251-2259.
• 3. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2260-2270.
• 4. Valent P, Hadzijusufovic E, Schernthaner GH et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015; 125(6): 901-906.
• 5. Quintás-Cardama A, Kantarjian H, O’brien S et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25(25): 3908-3914.
• 6. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125(17): 2128-2137.
• 7. Hoeper MM, Barst RJ, Bourge RC et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127(10): 1128-1138.
• 8. Shah NP, Wallis N, Farber HW et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90(11): 1060-1064.
• 9. Szmit S. Is dasatinib-related pulmonary hypertension a clinical concern? Future Oncol 2015; 11(18): 2491-2494.
• 10. Larson RA. Is there a best TKI for chronic phase CML? Blood 2015; 126(21): 2370-2375.
• 11. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 2015; 33(35): 4210-4218.
• 12. Kim TD, Rea D, Schwarz M et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27(6): 1316-1321.

• Document Type: minireview